Shorter versus longer corticosteroid duration and recurrent immune checkpoint inhibitor-associated AKI
Background Corticosteroids are the mainstay of treatment for immune checkpoint inhibitor-associated acute kidney injury (ICPi-AKI), but the optimal duration of therapy has not been established. Prolonged use of corticosteroids can cause numerous adverse effects and may decrease progression-free surv...
保存先:
| 主要な著者: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BMJ Publishing Group
2022-09-01
|
| シリーズ: | Journal for ImmunoTherapy of Cancer |
| オンライン・アクセス: | https://jitc.bmj.com/content/10/9/e005646.full |
| タグ: |
タグなし, このレコードへの初めてのタグを付けませんか!
|
